跳至主要内容
临床试验/NCT03807076
NCT03807076已完成不适用

Modulating the Glucose-dependent Insulinotropic Polypeptide (GIP) System in Patients With Acromegaly Due to a Pituitary Tumor

University of Copenhagen2 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2019年8月13日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
25
试验地点
2
主要终点
Growth hormone levels

研究概览

简要总结

Modulation of the GIP System in Patients With Acromegaly Due to a Pituitary adenoma

详细描述

Aim: To determine the importance of the GIP system in patients with acromegaly who has paradoxical growth hormone secretion during an oral glucose tolerance test (OGTT) using a GIP antagonist (GIP-A).

Thirty participants (age 18-75 years) with normal kidney and liver parameters and hemoglobin levels will be included in a placebo-controlled cross-over study. The study consists of two study days with concomitant infusions of A) GIP-A or B) saline (placebo).

A paradoxical growth hormone secretion to an OGTT is here defined as an increase in plasma growth hormone levels of ≥30% from baseline based on a mean value of the definitions in the literature.

Regazzo et al. (2017) European Journal of Endocrinology 176, 543-553 Mukai et al. (2018) The Journal of Clinical Endocrinology and Metabolism 104(5), 1637-1644 Hage et al. (2019) The Journal of Clinical Endocrinology and Metabolism 104(5), 1777-1787 Scaroni et al. (2019) J Clin Endocrinol Metab 104(3), 856-862

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients under clinical investigation of acromegaly disease with normal kidney function, liver function and hemoglobin levels.

排除标准

  • Medication for acromegaly, adenectomy, liver disease, uncontrolled anemia, severe heart disease, uncontrolled high blood pressure (>170/100 mmHg), current pregnancy

结局指标

主要结局

Growth hormone levels

时间窗: 240 min

Plasma growth hormone area under the curve (AUC)

次要结局

  • Glucose levels(240 min)
  • GIP levels(240 min)
  • Insulin-like growth factor-1 (IGF-1) levels(240 min)
  • GLP-1 levels(240 min)
  • GLP-2 levels(240 min)
  • Plasma triglyceride(240 min)
  • Insulin levels(240 min)
  • C-peptide levels(240 min)
  • Free fatty acids (FFA) levels(240 min)
  • Glucagon levels(240 min)
  • Ghrelin levels(240 min)
  • Plasma prolactin(240 min)
  • Plasma cholesterol(240 min)
  • Plasma TSH(240 min)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mette Høy Jensen

Industrial PhD student

University of Copenhagen

研究点 (2)

Loading locations...

相似试验

Modulating the GIP System in Patients With... | 临床试验